Your browser doesn't support javascript.
Seroprevalence of SARS-CoV-2 antibodies among Forcibly Displaced Myanmar Nationals in Cox's Bazar, Bangladesh 2020: a population-based cross-sectional study.
Rahman, Mahbubur; Khan, Samsad Rabbani; Alamgir, A S M; Kennedy, David S; Hakim, Ferdous; Evers, Egmond Samir; Afreen, Nawroz; Alam, Ahmed Nawsher; Islam, Md Sahidul; Paul, Debashish; Bhuiyan, Rijwan; Islam, Raisul; Moureen, Adneen; Salimuzzaman, M; Billah, Mallick Masum; Sharif, Ahmed Raihan; Akter, Mst Khaleda; Sultana, Sharmin; Khan, Manjur Hossain; von Harbou, Kai; Zaman, Mohammad Mostafa; Shirin, Tahmina; Flora, Meerjady Sabrina.
  • Rahman M; Epidemiology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh dr_mahbub@yahoo.com.
  • Khan SR; Epidemiology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Alamgir ASM; Virology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Kennedy DS; WHO Emergency Sub-Office, World Health Organization, Cox's Bazar, Bangladesh.
  • Hakim F; Research and Publication, World Health Organization Bangladesh, Dhaka, Bangladesh.
  • Evers ES; WHO Emergency Sub-Office, World Health Organization, Cox's Bazar, Bangladesh.
  • Afreen N; Epidemiology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Alam AN; Virology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Islam MS; Research and Publication, World Health Organization Bangladesh, Dhaka, Bangladesh.
  • Paul D; WHO Emergency Sub-Office, World Health Organization, Cox's Bazar, Bangladesh.
  • Bhuiyan R; Co-ordination Center, Ministry of Health and Family Welfare, Cox's Bazar, Bangladesh.
  • Islam R; WHO Emergency Sub-Office, World Health Organization, Cox's Bazar, Bangladesh.
  • Moureen A; IEDCR Field Laboratory, World Health Organization, Cox's Bazar, Bangladesh.
  • Salimuzzaman M; Zoonosis, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Billah MM; Epidemiology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Sharif AR; Epidemiology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Akter MK; Research and Publication, World Health Organization Bangladesh, Dhaka, Bangladesh.
  • Sultana S; Virology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Khan MH; Virology, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • von Harbou K; WHO Emergency Sub-Office, World Health Organization, Cox's Bazar, Bangladesh.
  • Zaman MM; Research and Publication, World Health Organization Bangladesh, Dhaka, Bangladesh.
  • Shirin T; Director, Institute of Epidemiology Disease Control and Research, Dhaka, Bangladesh.
  • Flora MS; Additional Director General, Directorate General of Health Services, Dhaka, Bangladesh.
BMJ Open ; 12(11): e066653, 2022 11 21.
Article in English | MEDLINE | ID: covidwho-2137793
ABSTRACT

OBJECTIVES:

The study aimed to determine the seroprevalence, the fraction of asymptomatic infections, and risk factors of SARS-CoV-2 infections among the Forcibly Displaced Myanmar Nationals (FDMNs).

DESIGN:

It was a population-based two-stage cross-sectional study at the level of households.

SETTING:

The study was conducted in December 2020 among household members of the FDMN population living in the 34 camps of Ukhia and Teknaf Upazila of Cox's Bazar district in Bangladesh.

PARTICIPANTS:

Among 860 697 FDMNs residing in 187 517 households, 3446 were recruited for the study. One individual aged 1 year or older was randomly selected from each targeted household. PRIMARY AND SECONDARY OUTCOME

MEASURES:

Blood samples from respondents were tested for total antibodies for SARS-CoV-2 using Wantai ELISA kits, and later positive samples were validated by Kantaro kits.

RESULTS:

More than half (55.3%) of the respondents were females, aged 23 median (IQR 14-35) years and more than half (58.4%) had no formal education. Overall, 2090 of 3446 study participants tested positive for SARS-CoV-2 antibody. The weighted and test adjusted seroprevalence (95% CI) was 48.3% (45.3% to 51.4%), which did not differ by the sexes. Children (aged 1-17 years) had a significantly lower seroprevalence 38.6% (95% CI 33.8% to 43.4%) compared with adults (58.1%, 95% CI 55.2% to 61.1%). Almost half (45.7%, 95% CI 41.9% to 49.5%) of seropositive individuals reported no relevant symptoms since March 2020. Antibody seroprevalence was higher in those with any comorbidity (57.8%, 95% CI 50.4% to 64.5%) than those without (47.2%, 95% CI 43.9% to 50.4%). Multivariate logistic regression analysis of all subjects identified increasing age and education as risk factors for seropositivity. In children (≤17 years), only age was significantly associated with the infection.

CONCLUSIONS:

In December 2020, about half of the FDMNs had antibodies against SARS-CoV-2, including those who reported no history of symptoms. Periodic serosurveys are necessary to recommend appropriate public health measures to limit transmission.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Child / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2022-066653

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Child / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2022-066653